Related Experiment Video
Updated: Oct 1, 2026
Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
[Detection of serum free insulin-like growth factor 1 in patients with chronic viral hepatitis]
Insights
Serum free insulin-like growth factor 1 (IGF-1) is lower in patients with liver cirrhosis and severe chronic hepatitis. Lower IGF-1 levels indicate a poorer prognosis in severe chronic hepatitis patients.
Area of Science:
- Hepatology
- Endocrinology
- Biochemistry
Background:
- Chronic viral hepatitis and liver cirrhosis are significant global health concerns.
- Liver dysfunction impacts various systemic functions, including growth factor regulation.
Purpose of the Study:
- To assess serum free insulin-like growth factor 1 (IGF-1) levels in patients with chronic viral hepatitis, liver cirrhosis, and severe chronic hepatitis.
- To investigate the correlation between serum free IGF-1 levels and disease severity and patient prognosis.
Main Methods:
- Serum free IGF-1 was quantified using ELISA.
- The study included 43 patients with chronic viral hepatitis, 20 with liver cirrhosis, and 12 with severe chronic hepatitis.
Main Results:
- Serum free IGF-1 levels were significantly reduced in patients with liver cirrhosis and severe chronic hepatitis.
- A serum free IGF-1 level below 0.2 ng/l was associated with mortality in severe chronic hepatitis patients.
- Patients with serum free IGF-1 above 0.3 ng/l had better survival outcomes.
- Reduced serum free IGF-1 correlated with lower albumin levels (< 30 g/l).
Conclusions:
- Serum free IGF-1 is diminished in liver cirrhosis and severe chronic hepatitis.
- Serum free IGF-1 serves as a potential biomarker for predicting prognosis in severe chronic hepatitis.
Objective:
To evaluate the serum free insulin-like growth factor 1 (IGF-1) level and its relation with the severity and prognosis in patients with chronic viral hepatitis, liver cirrhosis and severe chronic hepatitis.
Methods:
Serum free IGF-1 was detected by ELISA in 43 patients with chronic viral hepatitis, 20 with liver cirrhosis and 12 with chronic severe hepatitis.
Results:
Serum free IGF-1 was significantly decreased in patients with liver cirrhosis and severe chronic hepatitis. Five patients with chronic severe hepatitis whose serum free IGF-1 was lower than 0.2 ng/l died during follow-up. Four patients whose serum free IGF-1 above 0.3 ng/l survived. Serum free IGF-1 was significantly reduced in patients with albumin lower than 30 g/l.
Conclusions:
Serum free IGF-1 is decreased in patients with liver cirrhosis and severe chronic hepatitis and it can predict the prognosis of patients with severe chronic hepatitis.
